BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21550042)

  • 1. Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin.
    Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Hudson C
    Fertil Steril; 2011 Jun; 95(8):2715-7. PubMed ID: 21550042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization.
    Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Thomas S
    Fertil Steril; 2008 Jul; 90(1):231-3. PubMed ID: 17981269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support.
    Engmann L; Benadiva C
    Fertil Steril; 2012 Mar; 97(3):531-3. PubMed ID: 22245529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agonist trigger: what is the best approach? Agonist trigger and low dose hCG.
    Humaidan P
    Fertil Steril; 2012 Mar; 97(3):529-30. PubMed ID: 22154368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders.
    Griffin D; Benadiva C; Kummer N; Budinetz T; Nulsen J; Engmann L
    Fertil Steril; 2012 Jun; 97(6):1316-20. PubMed ID: 22480822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
    Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
    Fertil Steril; 2016 Aug; 106(2):330-3. PubMed ID: 27114332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates.
    Griffin D; Feinn R; Engmann L; Nulsen J; Budinetz T; Benadiva C
    Fertil Steril; 2014 Aug; 102(2):405-9. PubMed ID: 24842671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support.
    Castillo JC; Dolz M; Bienvenido E; Abad L; Casañ EM; Bonilla-Musoles F
    Reprod Biomed Online; 2010 Feb; 20(2):175-81. PubMed ID: 20113955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.
    Christopoulos G; Vlismas A; Carby A; Lavery S; Trew G
    Hum Fertil (Camb); 2016 Sep; 19(3):199-206. PubMed ID: 27662416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GnRH antagonist rescue of a long-protocol IVF cycle and GnRH agonist trigger to avoid ovarian hyperstimulation syndrome: three case reports.
    Martínez F; Rodríguez DB; Buxaderas R; Tur R; Mancini F; Coroleu B
    Fertil Steril; 2011 Jun; 95(7):2432.e17-9. PubMed ID: 21513932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GnRHa to trigger final oocyte maturation: a time to reconsider.
    Humaidan P; Papanikolaou EG; Tarlatzis BC
    Hum Reprod; 2009 Oct; 24(10):2389-94. PubMed ID: 19608565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective comparison of GnRH agonist trigger with HCG trigger in GnRH antagonist cycles in anticipated high-responders.
    Datta AK; Eapen A; Birch H; Kurinchi-Selvan A; Lockwood G
    Reprod Biomed Online; 2014 Nov; 29(5):552-8. PubMed ID: 25246126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
    Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
    J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos.
    Garcia-Velasco JA
    Fertil Steril; 2012 Mar; 97(3):527-8. PubMed ID: 22222191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian hyperstimulation syndrome prevention strategies: Luteal support strategies to optimize pregnancy success in cycles with gonadotropin-releasing hormone agonist ovulatory trigger.
    Engmann L; Benadiva C
    Semin Reprod Med; 2010 Nov; 28(6):506-12. PubMed ID: 21082510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles.
    Peñarrubia J; Balasch J; Fábregues F; Creus M; Casamitjana R; Ballescá JL; Puerto B; Vanrell JA
    Hum Reprod; 1998 Dec; 13(12):3315-8. PubMed ID: 9886506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of GnRH agonist alone or combined with different low-dose hCG on cumulative live birth rate for high responders in GnRH antagonist cycles: a retrospective study.
    He Y; Tang Y; Chen S; Liu J; Liu H
    BMC Pregnancy Childbirth; 2022 Mar; 22(1):172. PubMed ID: 35236312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropin-releasing hormone agonist trigger: the way to eliminate ovarian hyperstimulation syndrome--a 20-year experience.
    Kol S; Itskovitz-Eldor J
    Semin Reprod Med; 2010 Nov; 28(6):500-5. PubMed ID: 21082509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
    Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.